Beukenlaan 137
5616 VD Eindhoven
The Netherlands
+31 85064 55 82
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.
Author Archive for: 3wmedia
Entries by 3wmedia
Arctoris appoints three experienced industry executives to Advisory Board
Arctoris, an Oxford-based research company operating a fully automated drug discovery platform, has appointed three distinguished experts as members of its Advisory Board: Beth J Hoffman PhD, Prof. Khusru Asadullah MD, and Stanley Lapidus.
Carina Biotech to create cancer-busting CAR-T cells using Bionomics antibody
In an exclusive agreement with Bionomics Limited, Australia’s Carina Biotech will create Chimeric Antigen Receptor T cells (CAR-T cells) and other adoptive cell therapies to the leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5) using the first-in-class humanised antibody BNC101 developed by Bionomics.
BioMedion buys compliance division of arivis
BioMedion, a global Compliance Management Software company providing controlled content and raw data management solutions for the life science industry, has acquired the Compliance Division of arivis, a provider of regulatory software and biomedical 3D and big image data software solutions.
Nordic Capital, Astorg jointly acquire Cytel
Nordic Capital and Astorg have jointly acquired acquire Cytel Inc. from New Mountain Capital. Cytel is one of the largest providers of statistical software and advanced analytics for clinical trial design and biometrics execution.
LSBio acquires Absolute Antibody
Seattle, US-based LSBio, a leading provider of antibodies and life science research reagents, has acquired UK-based Absolute Antibody and its sister company Kerafast. Terms of the transaction were not disclosed.
European Commission’s Open Research Europe platform up and running
The new Open Research Europe (ORE) platform – funded by the European Commission – is now up and running.
Ovarian cancer project shows promise
Due to promising results, Porvair Sciences has agreed with its collaborative partners to make additional investment in the CEAT project which aims to dramatically improve the diagnosis and treatment of ovarian cancer.